Phase III trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
Thursday, April 21, 2011 - 16:30
in Health & Medicine
The SWOG trial S0421 closed early based on interim finding that atrasentan added to docetaxel and prednisone did not confer additional survival benefit to patients with advanced hormone-refractory prostate cancer.